newsfilter
← Latest News
Business Wire·

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

-- Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on